Seizures in tramadol overdoses reported in the ToxIC registry: predisposing factors and the role of naloxone

Abstract Importance: Tramadol prescriptions have increased as fewer schedule II and III drugs are prescribed. There has been a concomitant increase in overdoses and adverse events recorded in the National Poison Data System. Seizure activity after tramadol overdose or therapeutic use is a well-documented adverse event. The primary objective is to evaluate the characteristics associated with seizures following single agent tramadol ingestion. Secondarily we aim to compare the rate of seizures in individuals treated, and not treated, with naloxone. Methods: We searched the Toxicology Investigators Consortium data registry for all cases of single agent tramadol ingestions from 01/01/2014 through 12/31/2017. Descriptive statistics were used to evaluate characteristics associated with increased risk of seizures. Binary logistic regressions were used to evaluate the associations between seizures and age, race, acuity, intent, toxidromes, symptoms, and treatments. Results: There were 80 single ingestion tramadol cases entered into the registry. Seizures developed in 42 (52.5%) patients. Asian patients (OR = 7.2, 95% CI: 1.9–27.3, p = .004) and patients abusing or misusing tramadol (OR = 3.2, 95% CI: 1.2–8.3, p = .02) more likely to develop seizures. Patients exhibiting an opioid toxidrome were significantly less likely to develop seizures (OR = 0.12, 95% CI: 0.03–0.60). Ingestion of tramadol as a means of self-harm and age were not associated with an increased risk of seizures. There was no significant association between naloxone administration and seizures (OR = 0.30, 95% CI 0.07–1.25). Conclusions: Based on data from the ToxIC registry, tramadol induced seizures are more likely in Asian patients and those abusing or misusing the medication. There was no association found between the development of seizures and the use of naloxone.

[1]  W. Dale,et al.  Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. , 2018, The American journal of medicine.

[2]  B. Mégarbane,et al.  Is naloxone the best antidote to reverse tramadol-induced neuro-respiratory toxicity in overdose? An experimental investigation in the rat , 2018, Clinical toxicology.

[3]  J. Goodwin,et al.  Decline in opioid prescribing after federal rescheduling of hydrocodone products , 2018, Pharmacoepidemiology and drug safety.

[4]  D. Spyker,et al.  2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report , 2017, Clinical toxicology.

[5]  C. Schwarzer,et al.  The Opioid System in Temporal Lobe Epilepsy: Functional Role and Therapeutic Potential , 2017, Front. Mol. Neurosci..

[6]  P. Wax,et al.  The Toxicology Investigators Consortium Case Registry—the 2016 Experience , 2017, Journal of Medical Toxicology.

[7]  Randall Young,et al.  Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015 , 2017, MMWR. Morbidity and mortality weekly report.

[8]  P. Hantson Toxicant-Induced Seizures , 2017 .

[9]  L. Brown,et al.  Has the rescheduling of hydrocodone changed ED prescribing practices? , 2016, The American journal of emergency medicine.

[10]  P. Wax,et al.  The Toxicology Investigators Consortium Case Registry—the 2015 Experience , 2016, Journal of Medical Toxicology.

[11]  J. Pruszynski,et al.  Change in Prescription Habits After Federal Rescheduling of Hydrocodone Combination Products , 2016, Proceedings.

[12]  Roger Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[13]  John C Alexander,et al.  Analgesic utilization before and after rescheduling of hydrocodone in a large academic level 1 trauma center. , 2016, Journal of opioid management.

[14]  Ashley Haynes,et al.  Trends in analgesic exposures reported to Texas Poison Centers following increased regulation of hydrocodone , 2016, Clinical toxicology.

[15]  James S. Goodwin,et al.  Trends in Opioid Prescriptions Among Part D Medicare Recipients From 2007 to 2012. , 2016, The American journal of medicine.

[16]  P. Wax,et al.  The Toxicology Investigators Consortium Case Registry—the 2014 Experience , 2015, Journal of Medical Toxicology.

[17]  Karin A Mack,et al.  Trends in Opioid Analgesic-Prescribing Rates by Specialty, U.S., 2007-2012. , 2015, American journal of preventive medicine.

[18]  N. Ryan,et al.  Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely , 2015, Clinical toxicology.

[19]  R. Altman,et al.  PharmGKB summary: tramadol pathway. , 2014, Pharmacogenetics and genomics.

[20]  A. Sabzghabaee,et al.  Does Naloxone Prevent Seizure in Tramadol Intoxicated Patients? , 2014, International journal of preventive medicine.

[21]  P. Wax,et al.  The Toxicology Investigators Consortium Case Registry—The 2011 Experience , 2012, Journal of Medical Toxicology.

[22]  J. Brent,et al.  Recurrent Seizures in Tramadol Intoxication: Implications for Therapy Based on 100 Patients , 2012, Basic & clinical pharmacology & toxicology.

[23]  W. Zulmi,et al.  Impact of CYP2D6 Genetic Polymorphism on Tramadol Pharmacokinetics and Pharmacodynamics , 2012, Molecular Diagnosis & Therapy.

[24]  Jeffrey Brent,et al.  The Toxicology Investigators Consortium (ToxIC) Registry , 2011, Journal of Medical Toxicology.

[25]  O. Mehrpour,et al.  Factors Related to Seizure in Tramadol Poisoning and Its Blood Concentration , 2011, Journal of Medical Toxicology.

[26]  S. Abbasi,et al.  Efficacy and safety of naloxone in the management of postseizure complaints of tramadol intoxicated patients: a self-controlled study , 2010, Emergency Medicine Journal.

[27]  Ruopeng Sun,et al.  Protective effects of naloxone in two‐hit seizure model , 2010, Epilepsia.

[28]  A. B. Haghighi,et al.  TRAMADOL INDUCED SEIZURE: REPORT OF 106 PATIENTS , 2010 .

[29]  M. Abdollahi,et al.  Dose-independent occurrence of seizure with tramadol , 2009, Journal of Medical Toxicology.

[30]  R. Sansone,et al.  Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. , 2009, Psychiatry (Edgmont (Pa. : Township)).

[31]  I. Singh,et al.  Tramadol-induced seizurogenic effect: a possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway. , 2008, Basic & clinical pharmacology & toxicology.

[32]  R. Raffa,et al.  Unexceptional Seizure Potential of Tramadol or Its Enantiomers or Metabolites in Mice , 2008, Journal of Pharmacology and Experimental Therapeutics.

[33]  M. Abdollahi,et al.  Tramadol intoxication: a review of 114 cases , 2008, Human & experimental toxicology.

[34]  T. Aosaki,et al.  Compartment-Specific Modulation of GABAergic Synaptic Transmission by μ-Opioid Receptor in the Mouse Striatum with Green Fluorescent Protein-Expressing Dopamine Islands , 2007, The Journal of Neuroscience.

[35]  A. Hoeft,et al.  Concentrations of Tramadol and O‐desmethyltramadol Enantiomers in Different CYP2D6 Genotypes , 2007, Clinical pharmacology and therapeutics.

[36]  N. Prow,et al.  The opioid receptor antagonist, naloxone, protects spinal motor neurons in a murine model of alphavirus encephalomyelitis , 2007, Experimental Neurology.

[37]  Alvin C Bronstein,et al.  2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS) , 2007, Clinical toxicology.

[38]  Hui Zhang,et al.  Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population , 2006, European Journal of Clinical Pharmacology.

[39]  T. Albertson,et al.  Tramadol Exposures Reported to Statewide Poison Control System , 2005, The Annals of pharmacotherapy.

[40]  T. Sata,et al.  The Effects of Tramadol and Its Metabolite on Glycine, γ-Aminobutyric AcidA, and N-Methyl-d-Aspartate Receptors Expressed in Xenopus Oocytes , 2005, Anesthesia and analgesia.

[41]  M. Newton,et al.  Tramadol and new‐onset seizures , 2005, The Medical journal of Australia.

[42]  J. Brent Critical care toxicology : diagnosis and management of the critically poisoned patient , 2005 .

[43]  A. Hajrasouliha,et al.  The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice , 2004, Neuropharmacology.

[44]  R. Ismail,et al.  Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects. , 2002, Journal of pharmaceutical and biomedical analysis.

[45]  Bradford Ld CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[46]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[47]  C. Drinkard,et al.  Tramadol and Seizures: A Surveillance Study in a Managed Care Population , 2000, Pharmacotherapy.

[48]  B. Söderpalm,et al.  Naloxone antagonizes GABAA/benzodiazepine receptor function in rat corticohippocampal synaptoneurosomes , 2000, Journal of Neural Transmission.

[49]  D. Fife,et al.  The Risk of Seizures Associated with Tramadol , 1998, Pharmacotherapy.

[50]  D. Graham,et al.  Seizures reported with tramadol. , 1997, JAMA.

[51]  B. Benson,et al.  Prospective multicenter evaluation of tramadol exposure. , 1997, Journal of toxicology. Clinical toxicology.

[52]  H. Frenk Pro- and anticonvulsant actions of morphine and the endogenous opioids: Involvement and interactions of multiple opiate and non-opiate systems , 1983, Brain Research Reviews.

[53]  T. G. Smith,et al.  Naloxone antagonism of GABA-evoked membrane polarizations in cultured mouse spinal cord neurons , 1980, Brain Research.

[54]  L L Iversen,et al.  Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies. , 1978, European journal of pharmacology.

[55]  W. Martin,et al.  Antagonism of the convulsant effects of heroin, d-propoxyphene, meperidine, normeperidine and thebaine by naloxone in mice. , 1975, The Journal of pharmacology and experimental therapeutics.